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Abstract
Background:  Tetracycline-regulated systems have been used to control the expression of
heterologous genes in such diverse organisms as yeast, plants, flies and mice. Adaptation of this
prokaryotic regulatory system avoids many of the problems inherent in other inducible systems.
There have, however, been many reports of difficulties in establishing functioning stable cell lines
due to the cytotoxic effects of expressing high levels of the tetracycline transactivator, tTA, from
a strong viral promoter.
Results: Here we report the successful incorporation of tetracycline-mediated gene expression in
a mouse mammary epithelial cell line, HC11, in which conventional approaches failed. We
generated retroviruses in which tTA expression was controlled by one of three promoters: a
synthetic tetracycline responsive promoter (TRE), the elongation factor 1-alpha promoter (EF1)
or the phosphoglycerate kinase-1 promoter (PGK), and compared the resulting cell lines to one
generated using a cytomegalovirus immediate early gene promoter (CMV). In contrast to cells
produced using the CMV and PGK promoters, those produced using the EF1 and TRE promoters
expressed high levels of -galactosidase in a tetracycline-dependent manner.
Conclusions: These novel retroviral vectors performed better than the commercially available
system and may have a more general utility in similarly recalcitrant cell lines.
Background
The ability to control the spatial and temporal expression
of a transgene, either in cell culture or in transgenic ani-
mals, is a valuable tool in gene function studies. Constitu-
tive overexpression of a transgene over long periods in
culture may have several undesired effects that are inimi-
cal to its functional characterisation. This is particularly
true in the case of gene products with growth inhibitory or
toxic effects. Temporal and spatial control of transgene ex-
pression is conferred by the choice of heterologous pro-
moter. Many methods have been described to achieve this
aim in mammalian cells. Some of these methods involve
the use of endogenous mammalian proteins. These in-
clude the use of heat shock proteins [1–3], metal-
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lothionein [4], the glucocorticoid receptor [5], the
estrogen receptor [6], the progesterone receptor [7] and
the aryl hydrocarbon receptor [8]. The ecdysone receptor
of Drosophila melanogaster has also been used to confer lig-
and-dependent activation on heterologous transgenes in
vivo and in vitro[9]. Other approaches have harnessed
components from two well-understood paradigms of
prokaryotic gene regulation – the Lac repressor [10,11]
and the Tet repressor [12].
While all of the methods listed have been used in trans-
genic animals, the tetracycline-mediated method is one of
the most commonly used. It has a number of significant
advantages over the other systems. Mammals do not ex-
press an endogenous tetracycline repressor and systemic
administration of this antibiotic to animals over long pe-
riods is, in itself, innocuous. The method exploits the
properties of the E. coli Tn10-encoded tetracycline repres-
sor protein, TetR. TetR binds Tet operator (TetO) elements
in the Tn10 transposon and represses the transcription of
tetracycline resistance genes. The binding of tetracycline
to TetR results in the derepression of these genes [13].
Analysis of the structure of the TetR:tetracycline complex
revealed that binding of tetracycline alters the relative ori-
entation of the helix-turn-helix motifs thereby abolishing
the DNA binding of the repressor [14].
This system has been adapted to control the expression of
heterologous genes in mammalian cells by fusion of the
Tet Repressor to the VP16 transcriptional activation do-
main of Herpes simplex virus to produce the tetracycline
transactivator, tTA. Expression of this protein in mamma-
lian cells was shown to regulate the expression of a luci-
ferase transgene downstream of a tetracycline responsive
promoter (a minimal CMV promoter containing tandem
tetO sites) in a tetracycline-dependent manner [12]. The
utility of the system in in vivo transgenic models has been
demonstrated in yeast [15], plants [16], flies [17] and
mice [18]. The system was further improved by the identi-
fication in a random mutagenesis screen of a TetR variant
with reversed DNA-binding properties. This reverse tetra-
cycline transactivator, rtTA, activates transcription upon
ligand-binding [19].
Some attempts have been made to address problems of
cytotoxicity of the tTA protein as these can have a negative
impact on the successful generation of stable tetracycline-
regulated cell lines. The initial system used the strong viral
CMV promoter to drive tTA expression [12]. Plasmid vec-
tors in which the CMV promoter was replaced with weak-
er promoters were shown to significantly increase the
probability of establishing a functional cell line [20,21].
Generation of stable cell lines using plasmid vectors is typ-
ically inefficient and time-consuming, requiring the inte-
gration of the plasmid at a random chromosomal
breakpoint, often in resulting in multiple copies of the
plasmid at this locus. In contrast, the retroviral life cycle
includes a genomically integrated proviral stage so that
the use of recombinant retroviruses can lead to the rapid
and efficient generation of stable cell lines [22].
In this study, we compare the effect of the choice of pro-
moter used to drive tTA expression on the successful gen-
eration of stable -galactosidase-inducing cells using the
mouse mammary epithelial cell line, HC11 [23]. Attempts
to establish tetracycline-regulated gene expression in this
cell line using conventional approaches were unsuccess-
ful. The promoters evaluated are the cytomegalovirus im-
mediate early promoter (CMV), the mammalian
elongation factor 1-alpha (EF1) and phosphoglycerate
kinase-1 (PGK) promoters, and a tetracycline responsive
element consisting of seven 42 bp TetO repeats upstream
of a minimal CMV promoter (TRE). Of the four promoters
tested, both the EF1 and the TRE yielded cell lines in
which a -galactosidase transgene was regulated in a tetra-
cycline-dependent manner, while no induction was de-
tected in the case of the CMV and PGK promoters. These
novel retroviral vectors may have a general applicability in
cell lines in which commercially available tetracycline are
unsuccessful.
Results
HC11 cells stably infected with RevTetOFF(CMV-tTA) and 
TRE-lacZ fail to express -galactosidase in a tetracycline-
dependent manner
The RevTetOFF system (Clontech) was chosen to establish
tetracycline-regulated gene expression in a mouse mam-
mary epithelial cell line, HC11. This system consists of
two retroviral constructs – RevTetOFF in which tTA ex-
pression is under the control of the CMV promoter (CMV-
tTA), and RevTRE, containing a tetracycline responsive
promoter, into which the cDNA of interest can be cloned.
As this paper describes a number of variants of the com-
mercially available RevTetOFF vector, this original vector
will be henceforth referred to as CMV-tTA. As a prelimi-
nary experiment, HC11 cells were transiently transfected
with CMV-tTA and TRE-lacZ to investigate whether tetra-
cycline-mediated regulation of gene expression in this cell
line was a viable prospect. These cells expressed -galac-
tosidase in a tetracycline-dependent manner (data not
shown and Fig. 2B-II). Culture of transiently transfected
cells in either tetracycline (2 g/ml) or doxycycline (1 g/
ml) was sufficient to repress transgene expression in these
experiments.
A "double-stable" cell line, HC11(CMV-tTA/TRE-lacZ),
was generated using these retroviruses in serial infection
and antibiotic selection as described in Materials and
Methods. When these cells were induced for 48 hours by
doxycycline withdrawal, X-gal staining revealed no detect-BMC Molecular Biology 2002, 3 http://www.biomedcentral.com/1471-2199/3/13
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Figure 1
Lack of tTA expression prevents -galactosidase induction in HC11(CMV-tTA/TRE-lacZ) cells. The cells were transiently trans-
fected with the indicated constructs and were cultured either in the presence (A,C,E,G,H,I) or absence (B,D,F,H,J) of 1 g/
ml doxycycline for 48 hours. The CMV-lacZ expression vector was used as a positive control for -galactosidase expression.
The cells were fixed and stained for -galactosidase expression using X-gal 48 hours after transfection.BMC Molecular Biology 2002, 3 http://www.biomedcentral.com/1471-2199/3/13
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able increase in -galactosidase activity (Fig. 1A and 1B).
This induction time was adequate for HC11 cells tran-
siently transfected with these constructs. Increasing the in-
duction time did not lead to any increase in -
galactosidase activity.
Addition of tTA is necessary and sufficient to rescue the in-
duction in HC11 (CMV-tTA/TRE-lacZ) cells
As these cell pools were resistant to both G418 and hygro-
mycin B it was assumed that the retroviruses had become
stably integrated. To investigate the failure to obtain in-
ducible expression, these "double-stable" cells were tran-
siently transfected with the constructs used to generate the
retroviruses (Fig. 1). Co-transfection of both CMV-tTA
and TRE-lacZ led to a strong induction of -galactosidase
upon withdrawal of tetracycline, indicating that there are
no factors intrinsic to these cells which prevent tetracy-
cline-mediated gene regulation (Fig. 1G and 1H). Trans-
fection of TRE-lacZ alone into this pool led to no increase
in expression (Fig. 1E and 1F). Surprisingly, transfection
of CMV-tTA alone led to a strong induction of -galactos-
idase activity in the pool (Fig. 1C and 1D). This strongly
suggested that the expression level of tTA was the limiting
factor in the pool and that its absence was preventing the
induction of the lacZ transgene.
Effect of promoter choice on the generation of functional 
inducible cell lines
The results above suggested that tTA was limiting and pre-
vious reports indicated that the choice of promoter used
to drive tTA or rtTA expression affected the probability of
successfully generating a functional inducible cell line
Figure 2
Generation and analysis of modified RevTetOFF constructs. (A) Three additional constructs were generated in which the CMV
promoter was replaced by either the elongation factor 1-alpha or phosphoglycerate kinase-1 promoters, or a tetracycline
responsive element. (B) Parental HC11 cells were transiently co-transfected with the indicated constructs and maintained for
48 hours in the presence of absence of 1 g/ml doxycycline. The cells were fixed and stained for -galactosidase expression
using X-gal 48 hours after transfection.
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[20,21]. To address whether this was significant in the cell
line of interest, we generated three additional retroviral
constructs based on CMV-tTA (Fig. 2A). In these variants,
the CMV promoter was replaced with either the elonga-
tion factor 1-alpha (EF1) or phosphoglycerate kinase-1
(PGK) promoters or the same Tetracycline Responsive El-
ement (TRE) that confers inducibility on the transgenes in
this system. By using the TRE, it was hoped that an au-
toregulatory system would be created in which tTA would
be expressed at minimal levels in the presence of tetracy-
cline and, upon tetracycline withdrawal, would activate its
own transcription and the transcription of the TRE-lacZ
transgene. Transient co-transfection of TRE-lacZ with each
of these constructs led to the expression of -galactosidase
in a tetracycline-dependent manner, indicating that these
constructs were functioning as expected (Fig. 2B).
Each of these tTA-expressing retroviruses was used to gen-
erate a pool of stable cells, as previously described. Each
pool was then infected with the TRE-lacZ retrovirus. Fol-
lowing selection, the induction kinetics of each of these
"double-stable" pools was investigated using a CPRG-
based -galactosidase activity assay (Fig. 3). In agreement
with the previous results, the cells infected with the CMV-
tTA retrovirus yielded no detectable induction in this sen-
sitive assay. Similarly the PGK-tTA cells could not be in-
duced to express -galactosidase. Interestingly, a strong
induction was observed in the cell pools in which tTA ex-
pression was controlled by either the EF1 promoter or
the Tetracycline Responsive Element. This induction was
effectively repressed by culturing the cells in the presence
of 20 ng/ml tetracycline. When tetracycline was with-
drawn from cells cultured in 2 g/ml of the antibiotic, a
Figure 3
Analysis of the kinetics of -galactosidase induction in the HC11 cell pools with tTA under the control of the CMV, EF1, PGK
or TRE promoters. (A) Dose-response curve. 5000 cells were plated per well for each condition and -galactosidase activity
was determined after 72 hours of induction. (B) Time course of induction. 5000 cells were plated per well for each condition
and -galactosidase activity was measured after the indicated periods of induction. In both cases, the -galactosidase activity
has been normalised to the protein concentration of the sample. Results are presented as mean normalised -galactosidase
activity of three replicates  standard error.
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time course analysis showed a strong induction of -galac-
tosidase activity occurred between 24 and 48 hours (Fig.
3B). The expression of tTA in two independently generat-
ed TRE-tTA pools was examined by western blotting (Fig.
4). tTA was expressed in these lines in a tetracycline-de-
pendent manner, indicating that this system was func-
tioning in an autoregulatory manner as designed.
Discussion
In this study we have analysed the effect of the promoter
chosen to drive tTA expression on establishing tetracy-
cline-mediated transcriptional regulation in a mouse
mammary epithelial cell line, HC11. Although this was
feasible by transient transfection, this cell line was recalci-
trant to the generation of tetracycline-regulated stable
cells in our hands using the retrovirally-mediated RevTet-
OFF system (Clontech). We evaluated the effect of four
promoters in parallel in the context of the RevTetOFF vec-
tor – cytomegalovirus immediate early (CMV), elongation
factor 1-alpha (EF1), phosphoglycerate kinase-1 (PGK)
and Tetracycline Responsive Element (TRE). Of these,
only those cells in which either EF1 or TRE were used to
drive tTA expression yielded functional -galactosidase-
inducing cell lines. Use of the TRE resulted in an autoreg-
ulatory system in which tTA was not expressed at detecta-
ble levels prior to induction. Upon tetracycline
withdrawal, tTA activated both its own transcription and
that of the lacZ transgene.
While it is clearly advantageous to use either the EF1 or
TRE promoters to drive tTA expression in this system, the
reasons for the failure of the CMV and PGK promoters are
unclear. Overexpression of tTA has been shown to have a
growth inhibitory effect (Gallia 1998). It is possible that
the expression of this transgene at high levels from the
CMV or PGK promoters is detrimental to the cell. The lack
of inducibility in the cell pools obtained using these pro-
moters could be explained by either the death of tTA ex-
pressing cells or the rapid overgrowth of the culture by
non-tTA expressing cells. The mechanism of tTA toxicity
has been proposed to be squelching – the inhibition of
cell function by the sequestration of endogenous proteins
– first described in the case of GAL4 overexpression in
yeast [24]. The tTA protein is a fusion of the transcription-
al activation domain of VP16 and the DNA-binding do-
main of the tet Repressor. VP16 is a potent transcriptional
activator and binds to a large number of proteins involved
in the regulation of transcription – Host Cell Factor, Oct-
1, TBP, hTAFII31, TFIIA, TFIIB, TFIIH, PC4 and the RNA
polymerase II holoenzyme [25]. Expression of high levels
of a VP16 fusion protein is likely to reduce the available
cellular pool of these factors and consequently inhibit the
process of RNA transcription.
No tTA expression was detected by immunofluorescence
or western blotting in the cell lines in which the CMV pro-
moter was used to drive tTA expression in this study (data
not shown). The efforts of others to reduce the toxicity of
tTA initially focussed on the VP16 domain. Elimination of
the binding sites for other proteins by using only the ami-
no acid sequence required for transcriptional activation
produced a modified tTA that was tolerated at higher in-
tracellular concentrations while still retaining the ability
to modulate transgene expression in a ligand-dependent
manner [26]. The issue of VP16 toxicity has also been ad-
dressed by replacing this domain with a number of non-
viral transcriptional activation domains. Fusion of the
acidic p65 domain of NF-kB to the tet-repressor yielded a
functional tetracycline dependent transactivator [27]. A
more sensitive and potent transactivator has been pro-
duced by replacing the VP16 domain with a hybrid trans-
activation domain containing sequences from NF-kB p65
and Heat Shock Factor 1 [28]. The transcriptional activa-
tion domain of the ubiquitously expressed E2F4 protein
has also proved useful. In a parallel comparison with tTA
transfected cells, the E2F4 variant yielded a higher per-
centage of clones expressing the transactivator, and these
cells were not subject to the growth retarding effects of the
VP16 fusion protein [29]. Some success has been reported
using a plasmid-based autoregulatory system similar to
that described here [20], however the use of retroviruses as
described here should facilitate the more rapid generation
of functional cell lines.
Figure 4
Western Blot analysis of tTA expression in two independent
pools of TRE-tTA infected cells. The cells were induced for
72 hours. In pools 1 and 2, tTA is expressed in a tetracycline-
dependent manner, demonstrating that the system functions
in an autoregulatory manner. -catenin is used as a loading
control.
Tetracycline (2 µg/ml) - +- +
anti-β-catenin
anti-tTA
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Conclusions
There have been many anecdotal reports of difficulties in
establishing tetracycline-mediated gene expression in a
variety of cell lines. We believe that the EF1– and TRE-
tTA retroviral constructs described here may have a gener-
al applicability for the introduction of tetracycline-medi-
ated gene expression in otherwise recalcitrant systems.
Methods
Cell culture
All reagents were purchased from Sigma unless otherwise
noted. HC11 mouse mammary epithelial cells were cul-
tured in 5% CO2 at 37C in RPMI 1640, supplemented
with 10% Foetal Bovine Serum (PAA Laboratories, Linz,
Austria), 2 mM L-glutamine, 2.5 g/ml insulin, 5 ng/ml
epidermal growth factor and 50 g/ml gentamycin (Invit-
rogen) [23]. Cells infected with retroviruses encoding tTA
were routinely cultured in either 2 g/ml tetracycline or 1
g/ml doxycycline to repress transcription of the tetracy-
cline-regulated transgene.
Bosc23 cells were used to produce ecotropic retroviruses
[30]. Cells were transiently transfected with the appropri-
ate retroviral construct and the supernatant was collected
48 hours post-transfection. Polybrene was added to a final
concentration of 5 g/ml and the supernatant was added
to HC11 cells for 24 hours. HC11 cells were then subject-
ed to antibiotic selection using 250 g/ml G418 (Invitro-
gen) when selecting for RevTetOFF based constructs.
These pools were then infected with TRE-lacZ retroviruses
and subjected to antibiotic selection with 200 g/ml hy-
gromycin B (Invitrogen). These were the empirically de-
termined lowest concentrations of antibiotics required to
kill untransfected HC11 cells within seven days.
Generation of constructs
The RevTetOFF construct containing the CMV promoter
driving tTA expression and the empty RevTRE construct
were purchased from Clontech.
A BglII fragment containing the lacZ cDNA was excised
from the CMV-lacZ construct and sub-cloned into BamHI
digested RevTRE to make TRE-lacZ. To make the EF1-,
PGK- and TRE-tTA retroviral constructs, the tTA cDNA was
excised from RevTetOFF using HindIII and BamHI and
subcloned into the HindIII and BamHI sites of pBlue-
script (Stratagene) to make pSK-tTA. The EF1 promoter
from pEF6V5HisC (Invitrogen) was excised using HindIII
and subcloned into the HindIII site of pSK-tTA to make
pSK-EF1-tTA. The PGK promoter was excised from a
pPGK-Neo derived vector using XhoI and HindIII and
subcloned into the XhoI and HindIII sites of pSK-tTA to
make pSK-PGK-tTA. The Tetracycline Responsive Element
was excised from RevTRE using XhoI and HindIII and sub-
cloned into the XhoI and HindIII sites of pSK-tTA to make
pSK-TRE-tTA. The CMV-tTA cassette was excised from
RevTetOFF by BamHI digestion and the ends were filled in
with Klenow polymerase. The promoter-tTA cassettes
from each pSK-Promoter-tTA construct were excised with
XhoI and BamHI, the ends were filled in with Klenow
polymerase and they were subcloned into the blunt-end-
ed BamHI digested RevTetOFF construct to make the
EF1-tTA, PGK-tTA and TRE-tTA retroviral constructs.
Transient transfection
Transient transfections were performed using Lipo-
fectamine (Invitrogen) according to the manufacturer's
instructions. Briefly, 1.5  105 cells were plated in 3.5 cm
wells on the day prior to transfection. Each well was trans-
fected with a total of 1 g DNA under serum-free condi-
tions for six hours, after which the cells were washed and
incubated for a further 48 hours before assaying expres-
sion.
Western Blotting
Cell monolayers were rinsed twice with ice-cold Phos-
phate Buffered Saline and total cell lysates were prepared
by scraping cells into a minimal volume of 50 mM
Tris.HCl pH 7.5, 150 mM NaCl, 0.5% NP40 and Com-
plete™ protease inhibitor cocktail (Roche). The protein
content of the clarified total cell lysates was measured us-
ing the Biorad Protein Assay. Aliquots containing 80 g
protein from each sample were analysed by SDS-PAGE
[31], and transferred electrophoretically to a PVDF mem-
brane. Mouse monoclonal antibodies were used to detect
tTA (Clontech) and -catenin (Transduction Laborato-
ries). A HRP-conjugated anti-mouse antibody (Amersham
Pharmacia Biotech) was used as a secondary antibody in
both cases. Detection was by Enhanced Chemilumines-
cent Detection according to the manufacturer's instruc-
tions (Amersham Pharmacia Biotech).
-galactosidase activity assays
5000 cells from each cell line, for each condition, were
cultured in triplicate in 96 well plates for 72 hours, and
were lysed in situ by addition of 40 l 1  Reporter Lysis
Buffer (Promega) followed by two freeze-thaw cycles. The
protein concentration of 5 l of lysate was determined
and the -galactosidase activity of the remaining 35 l of
lysate was measured using a spectrophotometric chlo-
rophenol red -D-galactopyranoside (CPRG) assay. 175
l of a solution containing 5 mM CPRG, 60 mM
Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4,
0.14% (v/v) 2-mercaptoethanol was added to each well.
The rate of change of absorbance (at 575 nm) was meas-
ured using an MRX-TC spectrophotometer (Dynex Tech-
nologies) and this -galactosidase activity was normalised
to the protein concentration of each sample to control for
any variation in cell number.BMC Molecular Biology 2002, 3 http://www.biomedcentral.com/1471-2199/3/13
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Cell monolayers were stained for -galactosidase expres-
sion using 5-bromo-4-chloro-3-indolyl--D-galactopyra-
noside (X-gal). The cells were fixed for 5 minutes in 4%
(w/v) paraformaldehyde and incubated at 37C in a solu-
tion containing 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6, 2
mM MgCl2, 0.01% (v/v) sodium deoxycholate, 0.02%
NP40, 2.5 mM X-gal.
Authors' contributions
All experimental procedures were carried out by PK. PK,
TE and AA contributed to the design of the study. All au-
thors read and approved the final manuscript.
Acknowledgements
The Bosc23 cells were a gift of Maria Emanuela Cuomo and the CMV-lacZ 
expression vector was a gift of Trevor Dale. This work was supported by 
a Ph.D. studentship from the Institute of Cancer Research.
References
1. Kay RJ, Boissy RJ, Russnak RH, Candido EP: Efficient transcription
of a Caenorhabditis elegans heat shock gene pair in mouse
fibroblasts is dependent on multiple promoter elements
which can function bidirectionally. Mol Cell Biol 1986, 6:3134-
3143
2. Kothary R, Clapoff S, Darling S, Perry MD, Moran LA, Rossant J: In-
ducible expression of an hsp68-lacZ hybrid gene in transgen-
ic mice. Development 1989, 105:707-714
3. Schweinfest CW, Jorcyk CL, Fujiwara S, Papas TS: A heat-shock-in-
ducible eukaryotic expression vector. Gene 1988, 71:207-210
4. Mayo KE, Warren R, Palmiter RD: The mouse metallothionein-I
gene is transcriptionally regulated by cadmium following
transfection into human or mouse cells. Cell 1982, 29:99-108
5. Huang AL, Ostrowski MC, Berard D, Hager GL: Glucocorticoid
regulation of the Ha-MuSV p21 gene conferred by sequences
from mouse mammary tumor virus. Cell 1981, 27:245-255
6. Webster N, Jin JR, Green S, Hollis M, Chambon P: The yeast UASG
is a transcriptional enhancer in human HeLa cells in the pres-
ence of the GAL4 trans-activator. Cell 1988, 52:169-178
7. Wang Y, O'Malley BW Jr, Tsai SY, O'Malley BW: A regulatory sys-
tem for use in gene transfer.  Proc Natl Acad Sci U S A 1994,
91:8180-8184
8. Campbell SJ, Carlotti F, Hall PA, Clark AJ, Wolf CR: Regulation of
the CYP1A1 promoter in transgenic mice: an exquisitely
sensitive on-off system for cell specific gene regulation. J Cell
Sci 1996, 109:2619-2625
9. No D, Yao TP, Evans RM: Ecdysone-inducible gene expression
in mammalian cells and transgenic mice. Proc Natl Acad Sci U S
A 1996, 93:3346-3351
10. Hu MC, Davidson N: The inducible lac operator-repressor sys-
tem is functional in mammalian cells. Cell 1987, 48:555-566
11. Labow MA, Baim SB, Shenk T, Levine AJ: Conversion of the lac re-
pressor into an allosterically regulated transcriptional acti-
vator for mammalian cells. Mol Cell Biol 1990, 10:3343-3356
12. Gossen M, Bujard H: Tight control of gene expression in mam-
malian cells by tetracycline-responsive promoters. Proc Natl
Acad Sci U S A 1992, 89:5547-5551
13. Bertrand KP, Postle K, Wray LV Jr, Reznikoff WS: Overlapping di-
vergent promoters control expression of Tn10 tetracycline
resistance. Gene 1983, 23:149-156
14. Hinrichs W, Kisker C, Duvel M, Muller A, Tovar K, Hillen W, Saenger
W: Structure of the Tet repressor-tetracycline complex and
regulation of antibiotic resistance. Science 1994, 264:418-420
15. Gari E, Piedrafita L, Aldea M, Herrero E: A set of vectors with a
tetracycline-regulatable promoter system for modulated
gene expression in Saccharomyces cerevisiae.  Yeast 1997,
13:837-848
16. Weinmann P, Gossen M, Hillen W, Bujard H, Gatz C: A chimeric
transactivator allows tetracycline-responsive gene expres-
sion in whole plants. Plant J 1994, 5:559-569
17. Bello B, Resendez-Perez D, Gehring WJ: Spatial and temporal tar-
geting of gene expression in Drosophila by means of a tetra-
cycline-dependent transactivator system.  Development 1998,
125:2193-2202
18. Furth PA, St Onge L, Boger H, Gruss P, Gossen M, Kistner A, Bujard
H, Hennighausen L: Temporal control of gene expression in
transgenic mice by a tetracycline-responsive promoter. Proc
Natl Acad Sci U S A 1994, 91:9302-9306
19. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H:
Transcriptional activation by tetracyclines in mammalian
cells. Science 1995, 268:1766-1769
20. Gallia GL, Khalili K: Evaluation of an autoregulatory tetracy-
cline regulated system. Oncogene 1998, 16:1879-1884
21. Gopalkrishnan RV, Christiansen KA, Goldstein NI, DePinho RA, Fish-
er PB: Use of the human EF-1alpha promoter for expression
can significantly increase success in establishing stable cell
lines with consistent expression: a study using the tetracy-
cline-inducible system in human cancer cells. Nucleic Acids Res
1999, 27:4775-4782
22. Colosimo A, Goncz KK, Holmes AR, Kunzelmann K, Novelli G,
Malone RW, Bennett MJ, Gruenert DC: Transfer and expression
of foreign genes in mammalian cells. Biotechniques 2000, 29:314-
324
23. Ball RK, Friis RR, Schoenenberger CA, Doppler W, Groner B: Prol-
actin regulation of beta-casein gene expression and of a cy-
tosolic 120-kd protein in a cloned mouse mammary
epithelial cell line. EMBO J 1988, 7:2089-2095
24. Gill G, Ptashne M: Negative effect of the transcriptional activa-
tor GAL4. Nature 1988, 334:721-724
25. Flint J, Shenk T: Viral transactivating proteins. Annu Rev Genet
1997, 31:177-212
2 6 . B a r o n  U ,  G o s s e n  M ,  B u j a r d  H :  Tetracycline-controlled tran-
scription in eukaryotes: novel transactivators with graded
transactivation potential. Nucleic Acids Res 1997, 25:2723-2729
27. Urlinger S, Helbl V, Guthmann J, Pook E, Grimm S, Hillen W: The
p65 domain from NF-kappaB is an efficient human activator
in the tetracycline-regulatable gene expression system. Gene
2000, 247:103-110
28. Go WY, Ho SN: Optimization and direct comparison of the
dimerizer and reverse tet transcriptional control systems. J
Gene Med 2002, 4:258-270
29. Akagi K, Kanai M, Saya H, Kozu T, Berns A: A novel tetracycline-
dependent transactivator with E2F4 transcriptional activa-
tion domain. Nucleic Acids Res 2001, 29:E23
30. Pear WS, Nolan GP, Scott ML, Baltimore D: Production of high-
titer helper-free retroviruses by transient transfection. Proc
Natl Acad Sci U S A 1993, 90:8392-8396
31. Laemmli UK: Cleavage of structural proteins during the as-
sembly of the head of bacteriophage T4. Nature 1970, 227:680-
685
Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMedcentral will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Paul Nurse, Director-General, Imperial Cancer Research Fund
Publish with BMC and your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours - you keep the copyright
editorial@biomedcentral.com
Submit your manuscript here:
http://www.biomedcentral.com/manuscript/
BioMedcentral.com